Biogen/Elan Tysabri Combination Use Higher Than Expected Since Launch

Demand for Biogen Idec/Elan's Tysabri for combination use with other multiple sclerosis therapies has been greater than expected in the product's first two months on the market

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet